Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital

Objetive: The aim of this study was to identify the reasons for failure in adherence to imatinib mesylate treatment in chronic myeloid leukemia. Methods: A retrospective review was performed of 100 non-electronic records of patients with Ph+ chronic myeloid leukemia treated with imatinib mesylate. The study period was from January 2001 to January2011. Data were analyzed by Chi-Square and Correspondence analysis using the Statistical Analysis System software package. Results: At the beginning of treatment 41% of patients were in advanced stages of the disease. The unavailability of the drug (44.8%) and myelotoxicity (25.7%) were the most frequent reasons for interruption. The adherence rate was < 90% in 47% of the cases. The low adherence influenced the cytogenetic response (p-value = 0.020) and molecular response (p-value = 0.001). Very high adherence (> 95%) induced complete cytogenetic response, major cytogenetic response and major molecular response. Conclusion: The population of this study obtained lower-than-expected therapeutic responses compared to other studies.

Bibliographic Details

Main Authors:	Reis,Samuel Roosevelt Campos dos, Quixada,Acy Telles de Souza, Nunes,Sammara Tavares, Cid,Danielle Maria Camelo, Souza,Jacqueline Holanda de, Costa,Clara Maria Bastos Eloy da, Silveira,Carolina Bizelli, Cid,David Antonio Camelo, Oliveira,Mariana Fatima Cabral de
Format:	Digital revista
Language:	English
Published:	Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular 2013
Online Access:	http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842013000300174
Tags:	Add Tag No Tags, Be the first to tag this record!